|
|
|
|
|
27.05.25 - 14:03
|
Immutep′s Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded the study's prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectable soft tissue sarcoma (STS)....
|
|
|
15.05.25 - 05:36
|
Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial (Small Caps)
|
|
|
Late-stage biotechnology specialist Immutep (ASX: IMM) has achieved significant improvement in response rates compared to historical controls in a trial evaluating its first-line non-small cell lung cancer (NSCLC) treatment candidate. The assessment of eftilagimod alpha (efti) with Keytruda and chemotherapy has achieved high response rates in the multi-centre INSIGHT-003 trial, an investigator-initiated study conducted by […]
The post Immutep delivers major breakthrough with 59.6% response rate in lung cancer trial appeared first on Small Caps....
|
|
|
05.05.25 - 06:01
|
Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial (Small Caps)
|
|
|
Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase IIb trial to treat patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). The study, which evaluated eftilagimod alfa (efti) in combination with anti-PD-1 therapy Keytruda (pembrolizumab) as first-line therapy for […]
The post Immutep delivers strong survival results in efti-Keytruda head and neck cancer immunotherapy trial appeared first on Small Caps....
|
|
|
|
|
02.04.25 - 14:03
|
Immutep to Participate in Upcoming Investor Conferences (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:...
|
|
|
|
|
|
|
|
|
17.12.24 - 14:03
|
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761. Through the first three of five single ascending dose cohorts in healthy participants, there have been no treatment related adverse events....
|
|
|
|
|
12.12.24 - 14:18
|
Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive clinical results from Cohort B of the TACTI-003 (KEYNOTE-C34) Phase IIb trial. This study evaluates eftilagimod alpha (efti) in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in first line recurrent/metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with negative PD-L1 expression....
|
|
|
11.12.24 - 01:19
|
Australia′s Immutep rises on 3-week high after initiation of phase-3 trial (Reuters EN)
|
|
|
BUZZ-Australia's Immutep rises on 3-week high after initiation of phase-3 trial ** Shares of biotechnology company Immutep IMM.AX rise as much as 2.2% to A$0.348, their highest since Nov. 14 ** Co has announced initiation of phase-3 trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC) ** Says trial will include ove...
|
|
|
|
|
|
|
14.11.24 - 03:49
|
Immutep′s efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials (Small Caps)
|
|
|
Immutep (ASX: IMM) has presented new data from a Phase II investigator-initiated trial of eftilagimod alpha (efti) in combination with radiotherapy plus Keytruda (pembrolizumab) for patients with soft tissue sarcoma (STS). Based on preliminary analysis of 21 patients available for primary endpoint assessment, the trial at Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO) in […]
The post Immutep's efti combination therapies show strong efficacy in soft tissue sarcoma and lung cancer trials appeared first on Small Caps....
|
|
|
29.10.24 - 13:03
|
Immutep Quarterly Activities Report Q1 FY25 (GlobeNewswire EN)
|
|
|
SYDNEY, AUSTRALIA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, provides an update on its activities for the quarter ended 30 September 2024 (Q1 FY25)....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
